{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54","upperLimit":"76","value":"67"},{"groupId":"OG001","lowerLimit":"56","upperLimit":"79","value":"69"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"75"}],"units":"Participants"}],"description":"Progression free survival was defined as the time from date of randomisation to disease progression or death from any cause without progression whichever occurred first; otherwise, patients were censored at the date last known to be free of progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive induction chemotherapy comprising docetaxel, cisplatin, and fluorouracil. Treatment repeats every 21 days for 3 courses. Patients achieving a pathologic complete response at the primary site and a clinical complete response in the neck then receive carboplatin once weekly and undergo concurrent radiotherapy once daily, 5 days a week, for 7 weeks. Patients with a partial response at the primary site (i.e., positive biopsy), stable disease, or radiographic evidence of persistent disease in the neck receive docetaxel once weekly for 4 weeks and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.\n\ncisplatin : Given IV\n\nradiation therapy : Patients undergo radiation therapy once or twice daily, 5 days a week, for up to 7 weeks\n\ncarboplatin : Given IV\n\nfluorouracil : Given IV\n\ndocetaxel : Given IV","id":"OG000","title":"Arm I"},{"description":"Patients receive cisplatin IV on weeks 1 and 4 and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.\n\ncisplatin : Given IV\n\nradiation therapy : Patients undergo radiation therapy once or twice daily, 5 days a week, for up to 7 weeks","id":"OG001","title":"Arm II"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"5 years","title":"Progression-free Survival and Disease-specific Survival as Assessed by Disease Progression or Death and Log Rank Tests at the Median, and 2, 3, and 5 Years","type":"SECONDARY","unitOfMeasure":"percent of patients"}